A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
efficacy
24 Months
No
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2006_551
NCT00405054
December 2006
June 2009
Name | Location |
---|